Bridons research contributions include: Development of Drug Affinity Complex (DAC) technology for albumin binding and peptide half-life extension Identification and characterization of CJC-1295 as a long-lasting GRF analog with sustained growth hormone-releasing properties Pioneering work on maleimido-derivatized GHRH analogs and their bioconjugation to serum albumin Demonstration of 4-fold increase in growth hormone area-under-curve with optimized CJC-1295 formulation versus native GHRH Extensive in vitro and in vivo pharmacological characterization in rat and human models His 2005 publication in Endocrinology titled Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog remains the foundational reference for CJC-1295 research, establishing the peptides mechanism of action and pharmacokinetic profile that enabled subsequent clinical investigation
BPC-157, a gastric peptide, has been shown to accelerate wound healing, reduce inflammation, and promote angiogenesis, the formation of new blood vessels
Boosts collagen and elastin, reduces fine lines, improves firmness, accelerates cell turnover, and provides antioxidant protection against free radicals
As a water-soluble vitamin, B12 plays a vital role in energy production, nerve function, and DNA synthesis
Both Epithalon (with H) and Epitalon (without H) appear in the published research literature and across research-supply listings
